ABSI — Absci Corporation

Summary of Absci Corporation Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Revenue: $700,000 for Q4 2025, primarily from partnered programs.
• R&D Expenses: Increased to $25.3 million from $18.4 million year-over-year, driven by advancements in internal programs, particularly ABS-201.
• SG&A Expenses: Slightly decreased to $8.6 million from $8.8 million year-over-year.
• Net Cash Position: $144.3 million as of December 31, 2025, down from $152.5 million at the end of Q3 2025, expected to fund operations into 2028.
• Gains: Recorded a $5.1 million gain from the settlement of contingent consideration.

2. Strategic Updates and Business Highlights

• ABS-201 Development: Successfully dosed first three cohorts in Phase 1/2a trial with favorable emerging safety data. Expanded into endometriosis as a second indication.
• Clinical Progress: Plans to share preliminary safety and pharmacokinetics (PK) data in the first half of 2026, with interim proof-of-concept data for hair regrowth in the second half of 2026.
• Market Potential: ABS-201 targets a significant unmet need in both androgenetic alopecia (AGA) and endometriosis, with potential annual addressable markets exceeding $25 billion.
• Partnership Strategy: Ongoing discussions with multiple strategic partners for ABS-101, ABS-301, and ABS-501, allowing focus on ABS-201.

3. Forward Guidance and Outlook

• Clinical Timeline: Expecting interim data for ABS-201 in AGA by late 2026 and initiation of Phase 2 trial for endometriosis in Q4 2026.
• Regulatory Engagement: Plans to engage with the FDA regarding the clinical development strategy, potentially allowing for expedited development from Phase 1/2a to Phase 3.
• Market Readiness: Anticipating strong demand based on consumer surveys, with high interest in ABS-201 among current users of oral minoxidil.

4. Bad News, Challenges, or Points of Concern

• Market Competition: The emergence of new treatments for AGA, such as clascoterone and oral extended-release minoxidil, could increase competitive pressures.
• Regulatory Risks: Uncertainty regarding FDA approval processes and the potential need for additional clinical data could impact timelines.
• Clinical Trial Challenges: Developing ABS-201 for endometriosis may face complexities related to pain assessment and trial design, requiring careful planning to mitigate placebo effects.

5. Notable Q&A Insights

• Efficacy Expectations: Management emphasized the goal of achieving hair regrowth efficacy comparable to high-dose oral minoxidil, with a target of 35-40 hairs per square centimeter as a "home-run" outcome.
• Safety Profile: Early safety data from the SAD portion of the trial showed no concerning safety signals, which is encouraging for ongoing development.
• Market Dynamics: There is significant interest in ABS-201 among current users of standard care for AGA, indicating a potential for strong market adoption if approved.
• Partnership Discussions: Management is focused on securing the right partnerships rather than rushing into deals, indicating a strategic approach to collaborations.

Overall, Absci Corporation is positioned for potential growth with its lead program ABS-201, while navigating competitive and regulatory challenges in the biotech landscape.